‘Unprecedented’ pace of COVID-19 drug development pushing Madison companies to expand

One such company, California-based Humanigen, developed its COVID-19 therapy, lenzilumab, using Catalent products and further contracted with Catalent for development, manufacturing and commercialization services. Though still in clinical trials, Humanigen has reported positive results for patients who used lenzilumab, based on early data.